Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis

NCT05267262 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

43

Enrollment

INDUSTRY

Sponsor class

Conditions

Alport Syndrome
Focal Segmental Glomerulosclerosis

Interventions

DRUG: R3R01

Sponsor

River 3 Renal Corp.